Prof. Dr. Endre Ludwig is a Medical Doctor at the Semmelweis Medical University and specializes in Internal Medicine, Clinical Pharmacology and Infectology.
Prof. Dr Ludwig is involved in the Hungarian Society of Infectology and Clinical Microbiology, European Society of Clinical Microbiology and Infectious Disease, is the Secretary General of the Hungarian Society of Chemotherapy, and part of the Executive Committee of the Federation of European Societies of Chemotherapy and Infection. Prof. Dr. Ludwig is also a member of the Hungarian College of Infectologists and the Head of the College of Hungarian Infectologists.
His research areas mainly focus on clinical pharmacology and antimicrobials, treatment of nosocomial bacterial infections, treatment of UTI-s in special patient groups, antibiotic stewardship, respiratory tract infections (pneumonia in particular), evolution of bacterial resistance, impact of antibiotic use and vaccination and pneumococcal vaccines.
Prof. Dr. Ludwig regularly attends local and international conferences and symposiums as an invited speaker for over 28 years. He has published over 250 publications in Hungarian and English. He has authored and co-authored several books and book chapters, such as computers in clinical decision making, clinical pharmacology of antimicrobials, and pharmacodynamics effect of antimicrobials, nosocomial infections and practice of antibiotic therapy.
Areas of Expertise (5)
Semmelweis Egyetem: M.D., Medicine
Featured Articles (5)
Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitalsInternational Journal of Antimicrobial Agents
2006 Owing to increasing resistance rates in Europe, pharmacodynamic analyses were proposed to determine optimal empirical antibiotic therapy against Pseudomonas aeruginosa isolated in Hungary. Minimum inhibitory concentrations for 180 non-duplicate P. aeruginosa ...
Elevated antibody levels against Chlamydia pneumoniae, human HSP60 and mycobacterial HSP65 are independent risk factors in myocardial infarction and ischaemic heart diseaseAtherosclerosis
2004 The relative significance of traditional risk factors, chronic infections and autoimmune processes in the development of acute myocardial infarction (AMI) has not been fully elucidated...
Antibiotic policies in Central Eastern EuropeInternational Journal of Antimicrobial Agents
2004 To assess the antibiotic policies in Central Eastern European (CEE) countries, a questionnaire on the prevalence of resistance, antibiotic consumption data for ambulatory and hospital care and antibiotic policies, was mailed to national representatives...
Metabolic interactions of ciprofloxacinDiagnostic Microbiology and Infectious Disease
1990 The mechanism and clinical relevance of the inhibitory effect of ciprofloxacin on the metabolism of selected drugs were studied in patients with bacterial infections. In study A, antipyrine tests were carried out in two groups of patients taking 1000 mg (group 1) and 250 mg (group 2) of oral ciprofloxacin for 7–10 days...
The effect of ciprofloxacin on antipyrine metabolismJournal of Antimicrobial Chemotherapy
1988 The effect of multiple-dose ciprofloxacin on antipyrine metabolism was studied in patients suffering from bacterial infections. The patients were given antipyrine 15 mg/kg intravenously before and after ciprofloxacin treatment. The dosage of ciprofloxacin was ...